Product Description
OBP-301 is a conditionally-restricted, replication-competent adenovirus derived from human adenovirus type 5 (Ad-5) that adds a human Telomerase Reverse Transcriptase (hTERT) gene promoter; it replicates only in tumor cells to cause lysis. It may enhance RT and may cause immunogenic cell death. (Sourced from: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.TPS262)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chugai
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer
Phase 1: Head and Neck Cancer|Hepatocellular Carcinoma|Oncology Solid Tumor Unspecified|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06340711 | P2 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2026-04-01 |
|
| NRG-GI007 | P1 |
Active, not recruiting |
Adenocarcinoma|Esophageal Cancer|Squamous Cell Carcinoma|Gastrointestinal Cancer |
2024-10-01 |
|
| NCT03921021 | P2 |
Completed |
Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer |
2023-06-20 |
|
| jRCT2033200223 | P1 |
Completed |
Hepatocellular Carcinoma |
2022-03-30 |